Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bispecific Antibody Therapy vs ASCT as Consolidation for Newly Diagnosed, Standard Risk Multiple Myeloma
NCT07887984Phase 3Not yet recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2026
- Primary completion
- Aug 2033
01
Overview
A Phase 3 trial of teclistamab, talquetamab in multiple myeloma (MM), sponsored by Cancer and Leukemia Group B. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07887984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887984.